文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

德曲妥珠单抗：一种用于三阴性乳腺癌的新型抗体药物偶联物。

Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer.

作者信息

Schipilliti Francesca Matilde, Drittone Denise, Mazzuca Federica, La Forgia Daniele, Guven Deniz Can, Rizzo Alessandro

机构信息

Oncological Department, Sant'Andrea Hospital, University Sapienza in Rome, Rome, Italy.

Department of Clinical and Molecular Medicine, Sapienza University, Oncology Unit, Azienda Ospedialiera Universitaria Sant'Andrea, Rome, Italy.

出版信息

Heliyon. 2024 Mar 22;10(7):e28385. doi: 10.1016/j.heliyon.2024.e28385. eCollection 2024 Apr 15.

DOI:10.1016/j.heliyon.2024.e28385
PMID:38560142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10981107/
Abstract

Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.

摘要

三阴性乳腺癌（TNBC）是预后最差的乳腺癌亚型，原因在于缺乏有效的治疗方案及其分子特征。近来，抗体药物偶联物（ADCs）极大地改变了乳腺癌的治疗格局；抗TROP2抗体药物偶联物戈沙妥珠单抗已获批用于治疗既往接受过治疗的转移性TNBC患者。新型抗体药物偶联物德曲妥珠单抗（Dato-DXd）最近在TNBC治疗中显示出令人鼓舞的结果。在本文中，我们总结并讨论了关于这种靶向TROP-2药物的作用机制和药理活性的现有数据，描述了该药物疗效和安全性的初步结果，并报告了主要正在进行的临床试验的特点、纳入标准和终点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aba/10981107/4a1a43823f46/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aba/10981107/4a1a43823f46/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aba/10981107/4a1a43823f46/gr1.jpg

相似文献

[1]
Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer.

Heliyon. 2024-3-22

[2]
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

Future Oncol. 2023-11

[3]
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.

Ther Adv Med Oncol. 2024-4-29

[4]
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.

Future Oncol. 2024-3

[5]
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.

Breast. 2022-12

[6]
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.

Curr Oncol. 2023-11-29

[7]
Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis.

Cancer Treat Res Commun. 2023

[8]
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.

Cancer Treat Rev. 2024-4

[9]
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.

Gynecol Oncol. 2024-10

[10]
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.

Mol Cancer Ther. 2021-12

引用本文的文献

[1]
Immune-related genes can accurately predict survival in bladder cancer: a retrospective study via two independent immunotherapy cohorts.

Transl Androl Urol. 2025-6-30

[2]
How has the field of immunogenic cell death in breast cancer evolved and impacted clinical practice over the past eleven years?

Hum Vaccin Immunother. 2025-12

[3]
Datopotamab Deruxtecan: First Approval.

Drugs. 2025-5-5

[4]
Targeting Triple-Negative Breast Cancer: Resistance Mechanisms and Therapeutic Advancements.

Cancer Med. 2025-5

[5]
Identification of chromatin remodeling-related gene signature to predict the prognosis in breast cancer.

Clin Exp Med. 2025-5-3

[6]
A study on the impact of neoadjuvant therapy on molecular subtype conversion in breast cancer.

World J Surg Oncol. 2025-4-22

[7]
TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.

Cancer Lett. 2025-6-28

[8]
Subsequent primary cancer risk and mortality among premenopausal breast cancer survivors.

Sci Rep. 2025-3-28

[9]
Machine learning Nomogram for Predicting endometrial lesions after tamoxifen therapy in breast Cancer patients.

Sci Rep. 2025-1-6

[10]
Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review.

Curr Neurol Neurosci Rep. 2024-12-3

本文引用的文献

[1]
Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead.

Curr Treat Options Oncol. 2023-5

[2]
Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.

Breast. 2023-4

[3]
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.

Int J Cancer. 2023-5-15

[4]
Trop-2 as a Therapeutic Target in Breast Cancer.

Cancers (Basel). 2022-11-30

[5]
Antibodies to watch in 2023.

MAbs. 2023

[6]
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?

Cancer J.

[7]
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.

Breast. 2022-12

[8]
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.

Future Oncol. 2022-9

[9]
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.

NPJ Breast Cancer. 2022-8-29

[10]
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.

Breast Cancer Res Treat. 2022-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索